Modality
Vaccine
MOA
MDM2i
Target
AHR
Pathway
Hedgehog
Migraine
Development Pipeline
Preclinical
~Nov 2021
→ ~Feb 2023
Phase 1
May 2023
→ May 2028
Phase 1Current
NCT04103927
1,706 pts·Migraine
2023-05→2028-05·Recruiting
1,706 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-242.1y awayPh2 Data· Migraine
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2028-05-24 · 2.1y away
Migraine
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04103927 | Phase 1/2 | Migraine | Recruiting | 1706 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR |